Bausch Health Canada says Quebec lists PrOKEDI on public drug formulary for schizophrenia

• Bausch Health subsidiary Bausch Health Canada secured public reimbursement in Quebec for PrOKEDI risperidone extended-release injection for adult schizophrenia.
• RAMQ added the 75 mg, 100 mg strengths to its formulary effective June 25, 2026.
• Listing follows reimbursement negotiations concluded earlier this year with the pan-Canadian Pharmaceutical Alliance.
• Drug is positioned as a 4-week injectable that does not require a loading dose or oral supplementation.
• Bausch Health Canada is pursuing listings in other provinces under their reimbursement processes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch Health Companies Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.